You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

glycine receptor antibody

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Healthy Trial in Qingdao (VDJ001, Placebo)

Completed
  • Healthy
  • Qingdao, Shandong, China
    the Affliated Hospital of Qingdao University
Aug 30, 2023

HER2+ Advanced Breast Cancer, Other Solid Tumors Trial (ADCC-R-Epo-R T-cells + Trastuzumab, Erythropoietin beta, Fludarabine and

Not yet recruiting
  • HER2+ Advanced Breast Cancer
  • Other Solid Tumors
  • ADCC-R-Epo-R T-cells + Trastuzumab
  • +2 more
  • (no location specified)
Aug 31, 2023

Lung Cancer Trial in Houston (Cemiplimab, Kevzara (Sarilumab))

Not yet recruiting
  • Lung Cancer
  • Houston, Texas
    M D Anderson Cancer Center
Jan 19, 2023

Thyroid Eye Disease Trial (VRDN-001 10 mg/kg Drug:)

Not yet recruiting
  • Thyroid Eye Disease
  • VRDN-001 10 mg/kg Drug:
  • (no location specified)
Sep 7, 2023

Stiff-Person Syndrome Trial in Rochester (Intravenous Immunoglobulins, Human, Placebos)

Withdrawn
  • Stiff-Person Syndrome
  • Intravenous Immunoglobulins, Human
  • Placebos
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Jun 11, 2019

Cancer, Tumor, Solid, Advanced Solid Tumor Trial in Houston (NTX-1088, Pembrolizumab)

Recruiting
  • Cancer
  • +4 more
  • Houston, Texas
    The University of Texas MD Anderson Cancer Center
Jan 24, 2023

Advanced Solid Tumor Trial in Bethesda, Boston (STAR0602)

Recruiting
  • Advanced Solid Tumor
  • Bethesda, Maryland
  • +1 more
Jan 6, 2023

Breast Cancer Trial (Trastuzumab Deruxtecan)

Not yet recruiting
  • Breast Cancer
  • Trastuzumab Deruxtecan
  • (no location specified)
Jul 10, 2023

Idiopathic Multicentric Castleman's Disease Trial in Beijing, Chengdu (Recombinant Humanized Anti-interleukin-6 Receptor

Recruiting
  • Idiopathic Multicentric Castleman's Disease
  • Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 4mg/kg
  • +2 more
  • Beijing, China
  • +2 more
Apr 26, 2022

Solid Tumor, Adult, EphA2 Overexpression, KRAS G12V Trial in Beijing (KRAS-EphA-2-CAR-DC, Abraxane, Cyclophosphamide)

Recruiting
  • Solid Tumor, Adult
  • +4 more
  • KRAS-EphA-2-CAR-DC
  • +3 more
  • Beijing, Beijing, China
    Biotherapeutic Department of Chinsese PLA Gereral Hospital
Nov 29, 2022

Solid Tumor, Adult, Lymphoma, EphA2 Overexpression Trial in Beijing (TP53-EphA-2-CAR-DC, Abraxane, Cyclophosphamide)

Recruiting
  • Solid Tumor, Adult
  • +6 more
  • TP53-EphA-2-CAR-DC
  • +3 more
  • Beijing, Beijing, China
    Biotherapeutic Department of Chinsese PLA Gereral Hospital
Nov 29, 2022

Clinical Phenotypes in Pericarditis: IL-1RA Antibodies and suPAR

Not yet recruiting
  • Pericarditis
  • IL1RA Antibody Assay
  • suPAR Testing
  • Homburg, Germany
  • +8 more
Jun 22, 2023

Myasthenia Gravis, MuSK Trial in Cleveland, Philadelphia (Amifampridine Phosphate)

Active, not recruiting
  • Myasthenia Gravis, MuSK
  • Amifampridine Phosphate
  • Cleveland, Ohio
  • +1 more
Jul 21, 2022

Axial Spondyloarthritis (axSpA), Ankylosing Spondylitis (AS) Trial in Marseille (blood samples)

Completed
  • Axial Spondyloarthritis (axSpA)
  • Ankylosing Spondylitis (AS)
  • blood samples
  • Marseille, France
    Assistance Publique Hopitaux de Marseille
Aug 31, 2022

Rhabdomyosarcoma, Rhabdomyosarcoma, Alveolar, Rhabdomyosarcoma, Embryonal Trial in Los Angeles, Bethesda (Dasatinib, Ganitumab)

Terminated
Has Results
  • Rhabdomyosarcoma
  • +2 more
  • Los Angeles, California
  • +1 more
Mar 17, 2022

Psycho-social Impact of Anti-NMDAR Encephalitis

Not yet recruiting
  • NMDAR Antibody-associated Auto-immune Encephalitis
  • standardized and validated surveys
  • Bron, France
    Centre de référence des syndromes neurologiques paranéoplasiques
Jul 13, 2023

Metastatic Colorectal Cancer Trial in Australia (Sodium Valproate, Panitumumab, Cetuximab)

Recruiting
  • Metastatic Colorectal Cancer
  • Sodium Valproate
  • +2 more
  • Saint Leonards, New South Wales, Australia
  • +8 more
Jan 22, 2023

Metastatic Lung Non-Small Cell Carcinoma, Refractory Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer American Joint

Recruiting
  • Metastatic Lung Non-Small Cell Carcinoma
  • +4 more
  • Necitumumab
  • +4 more
  • Los Angeles, California
    UCLA / Jonsson Comprehensive Cancer Center
Jan 5, 2023

SLE (Systemic Lupus), Sjogren's Syndrome, Systemic Scleroderma Trial in Taiyuan (CD19 targeted CAR-T cells)

Recruiting
  • SLE (Systemic Lupus)
  • +4 more
  • CD19 targeted CAR-T cells
  • Taiyuan, Shanxi, China
    Shanxi Bethune Hospital
Sep 25, 2023

Hepatocellular Carcinoma (HCC) Trial in Nancy, Paris (Pexastimogene Devacirepvec (Pexa Vec), Nivolumab)

Terminated
Has Results
  • Hepatocellular Carcinoma (HCC)
  • Nancy, France
  • +1 more
Oct 21, 2021

Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8

Active, not recruiting
Has Results
  • Anatomic Stage II Breast Cancer AJCC v8
  • +16 more
  • Durvalumab
  • Tremelimumab
  • Houston, Texas
    M D Anderson Cancer Center
Aug 18, 2022

Ovarian Cancer, Ovarian Carcinoma, Ovary Cancer Trial in United States (STRO-002, Bevacizumab)

Recruiting
  • Ovarian Cancer
  • +4 more
  • Tampa, Florida
  • +5 more
Aug 1, 2022

Generalized Lipodystrophy Trial in Worldwide (Placebo, Low-Dose REGN4461, High-dose REGN4461)

Active, not recruiting
  • Generalized Lipodystrophy
  • Placebo
  • +2 more
  • Bethesda, Maryland
  • +7 more
Mar 9, 2022

Medullary Thyroid Carcinoma Trial in Angers, Nantes, Saint-Herblain (• TF2 and 68 Ga-IMP-288)

Completed
  • Medullary Thyroid Carcinoma
  • • TF2 and 68 Ga-IMP-288
  • Angers, France
  • +2 more
Jul 22, 2022

Moderate to Severe Active Rheumatoid Arthritis Trial in Beijing (HS628+MTX, Actemra +MTX)

Completed
  • Moderate to Severe Active Rheumatoid Arthritis
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
Sep 14, 2023